|1.||Pulmonary Hypertension (Ayerza Syndrome)
08/01/1984 - "We employed chlorphentermine (CP), an anorexic drug of amphiphilic physicochemical properties, to unravel possible mechanisms underlying drug-induced pulmonary hypertension associated with this class of drugs. "
01/01/1982 - "Chlorphentermine (CP), an anorectic agent currently in use, is known to be highly accumulated in the lung, causes pulmonary phospholipidosis, and has been suspected of causing pulmonary hypertension. "
11/01/1982 - "Chlorphentermine (CP) is known to be highly accumulated by the lung, to cause pulmonary phospholipidosis and has been suspect in causing pulmonary hypertension possibly by inhibiting the clearance of 5-hydroxytryptamine (5-HT). "
06/01/1994 - "Chlorphentermine-induced lipidosis in the rat retina: a functional and morphological study."
01/01/1983 - "The present study was undertaken to clarify whether or not chlorphentermine-induced lipidosis in the proximal tubules of the rat kidney interferes with lysosomal degradation of an absorbed exogenous protein. "
03/01/1999 - "Chlorphentermine caused pronounced lipidosis in the pigment epithelium and less numerous in the neuroretina after 16 weeks; no photoreceptor cell degeneration was found. "
06/01/1994 - "Chronic administration of the cationic amphiphilic anorexigenic drug chlorphentermine to rats has previously been shown to induce extraocular and ocular lipidosis: large numbers of lipidosis-related cytoplasmic inclusions can be found in the pigment epithelium and smaller numbers in the neuroretina. "
01/01/1993 - "Experimental chlorphentermine lipidosis of the retina in albino rats."
|3.||Body Weight (Weight, Body)
06/01/1994 - "In the present study, female albino Wistar rats were treated orally with chlorphentermine (30-45 mg/kg body weight) for 4-16 weeks. "
01/01/1976 - "Ultrastructural and biochemical studies were carried out on three groups of experimental models which were induced by a single subcutaneous daily dose of 10 to 40 mg./kg. body weight of chlorphentermine hydrochloride. "
01/01/1982 - "Concurrently, neonates of the chlorphentermine-treated dams displayed a significant decrease in body weight in comparison to controls. "
12/01/1976 - "After the confrontation of their own data those of some other researchers, the authors recommend desopimon as a suitable additive means in the treatment of simple nutritive (hyperphagic) obesity."
12/01/1976 - "The authors tested the tolerance and therapeutic effect of desopimon preparation (1-p-chlorophenyl-2-aminopropane hydrochloride) in 44 subjects with obesity--I, II and III degree. "
12/01/1976 - "[Desopimon in the treatment of obesity]."
01/01/1974 - "Neuro-ophthalmologic observations in obesity during anorexigenic (Desopimon-EGYT) treatment."
09/01/1972 - "[Effect of desopimon on the coagulation system of the blood in obesity]."
02/15/1981 - "Effects of hyperoxia on pulmonary metabolism of newborn rats and modification by chlorphentermine."
01/01/1981 - "In contrast, hyperoxia altered the responsiveness of newborns to 20 mg/kg chlorphentermine as evidenced by the presence of foam cells. "
01/01/1981 - "Modification by hyperoxia of chlorphentermine- or phentermine- induced effects on newborn rat lung morphology and metabolism."
01/01/1981 - "Data suggest that the chlorphentermine-induced increase in DNA synthesis in newborn lung seems independent of changes in cyclic AMP and tha modification of drug-induced alterations by hyperoxia may be related to the chemical structure of a compound."
|1.||Serotonin (5 Hydroxytryptamine)
|7.||Chlorphentermine (Chlorphentermine Hydrochloride)
|9.||Pyruvic Acid (Pyruvate)